Fluticasone propionate

Generic Name: Fluticasone propionate

Brand Names: Advair, Airduo, Airduo Respiclick, Aller-flo, Armonair, Beser, Cutivate, Dymista, Flonase, Flovent, Fluticare, Ticanase, Wixela, Xhance

Drug Type: Small Molecule

Chemical Formula: C_₂₅H_₃₁F_₃O_₅S

CAS Number: 80474-14-2

Unique Ingredient Identifier: O2GMZ0LF5W

Background: Fluticasone propionate is a synthetic glucocorticoid. These drugs are available as inhalers, nasal, sprays, and topical treatments for various inflammatory indications. Fluticasone propionate was first approved in 1990.

Indication: Fluticasone propionate is indicated as an inhaler for the treatment and management of asthma by prophylaxisas well as inflammatory and pruritic dermatoses. Fluticasone propionate nasal spray is indicated for managing allergic and nonallergic rhinitis.

Associated Conditions: Allergic Rhinitis (AR), Allergy to Animal Dander, Allergy to Mold, Allergy to Tree Pollen, Asthma, Bacterial Sinusitis, Chronic Bronchitis, Chronic Obstructive Pulmonary Disease (COPD), Chronic Sinusitis, Dermatitis, Emphysema, Eosinophilic Esophagitis, House Dust Mite Allergy, House dust allergy, Itching of the nose, Nasal Congestion, Non-Allergic Rhinitis, Rhinitis, Rhinitis Perennial, Rhinorrhoea, Seasonal Allergic Rhinitis, Sneezing, Moderate, severe Perennial Allergic Rhinitis (PAR), Moderate, severe Seasonal Allergic Rhinitis

Clinical Trials

A Pilot Bioequivalence Study Between Fluticasone Propionate 250 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 250/50 Inhalation Powder/GSK in Healthy Volunteers

Phase 1

Completed

Conditions: Bioequivalence

Interventions: Drug: ADVAIR DISKUS® 250/50
Drug: Fluticasone propionate 250 mcg and salmeterol xinafoate 50 mcg/Respirent

First Posted Date: 2020-07-08

Last Posted Date: 2021-01-20

Lead Sponsor: Respirent Pharmaceuticals Co Ltd.

Target Recruit Count: 14

Registration Number: NCT04462822

Locations: 🇬🇷
BECRO Clinical Facility, Larissa, Thessaly, Greece

Topical Nasal Fluticasone Propionate in the Control of Allergic Rhinitis SymptomsPerene

Phase 3

Completed

Conditions: Perennial Allergic Rhinitis

Interventions: Drug: Fluticasone Propionate

First Posted Date: 2020-04-03

Last Posted Date: 2020-04-08

Lead Sponsor: Libbs Farmacêutica LTDA

Target Recruit Count: 566

Registration Number: NCT04332978

Efficacy and Safety APT-1011 in Adult Subjects With Eosinophilic Esophagitis (EoE) (FLUTE-2)

Phase 3

Completed

Conditions: Eosinophilic Esophagitis

Interventions: Drug: APT-1011
Drug: Placebo oral tablet
Procedure: Esophagogastroduodenoscopy

First Posted Date: 2020-02-24

Last Posted Date: 2023-06-12

Lead Sponsor: Ellodi Pharmaceuticals, LP

Target Recruit Count: 143

Registration Number: NCT04281108

Locations: 🇺🇸
Gastro Center of Maryland, Columbia, Maryland, United States
🇺🇸
Henry Ford Health System, Novi, Michigan, United States
🇺🇸
DBC Research USA, Pembroke Pines, Florida, United States

and more 53 locations

Hypertonic Versus Isotonic Saline Irrigations for Chronic Rhinosinusitis

Phase 2

Withdrawn

Conditions: Chronic Rhinosinusitis (Diagnosis)

Interventions: Drug: Isotonic saline
Drug: Hypertonic Nasal Wash
Drug: Fluticasone Propionate

First Posted Date: 2020-01-27

Last Posted Date: 2021-03-18

Lead Sponsor: Stanford University

Registration Number: NCT04242368

Locations: 🇺🇸
Stanford University, Stanford, California, United States

Personalized Treatment Algorithms for Difficult-to-treat Asthma

Phase 2

Completed

Conditions: Asthma in Children

Interventions: Drug: Cholecalciferol
Drug: antihistamine
Drug: Azithromycin
Drug: emollient cream
Drug: Fluticasone Propionate
Drug: Asthma Controller Medication

First Posted Date: 2019-11-27

Last Posted Date: 2021-08-20

Lead Sponsor: Children's Hospital Medical Center, Cincinnati

Target Recruit Count: 21

Registration Number: NCT04179461

Locations: 🇺🇸
Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States

The Causal Relation of Nasal Nitric Oxide Levels to the Severity of Chronic Rhinosinusitis and Its Inflammatory Phenotype

Not Applicable

Active, not recruiting

Conditions: Chronic Rhinosinusitis (Diagnosis)

Interventions: Drug: Fluticasone Propionate

First Posted Date: 2019-11-20

Last Posted Date: 2023-05-09

Lead Sponsor: Tampere University Hospital

Target Recruit Count: 88

Registration Number: NCT04171167

Locations: 🇫🇮
Tampere University Hospital, Tampere, Finland

Study Evaluating the Efficacy and Safety of Intranasal Administration of OPN-375 in Subjects With Chronic Rhinosinusitis Without the Presence of Nasal Polyps

Phase 3

Completed

Conditions: Chronic Rhinosinusitis

Interventions: Drug: OPN-375

First Posted Date: 2019-05-23

Last Posted Date: 2023-12-21

Lead Sponsor: Optinose US Inc.

Target Recruit Count: 223

Registration Number: NCT03960580

Locations: 🇺🇸
BioSolutions Clinical Research Center, La Mesa, California, United States
🇺🇸
Best Clinical Trials, New Orleans, Louisiana, United States
🇳🇿
Optimal Clinical Trials, Auckland, New Zealand

and more 84 locations

Legend: TRELEGY Real World Chronic Obstructive Pulmonary Disease (COPD) Effectiveness Study

Phase 4

Withdrawn

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Drug: Inhaled corticosteroids/long-acting beta2-adrenergic/long-acting muscarinic receptor antagonists
Drug: Fluticasone furoate/umeclidinium/vilanterol